Eric Dein
2 years 11 months ago
Petri @jhrheumatology data on SGLT2i in SLE
A#1490 #ACR23 @RheumNow
Prior to Rx, average annual change in eGFR was -3.1
After starting SGLT2i, average change decr to -0.9
Did not reach signif (p=0.27)
Average annual incr in UPCR was 0.4 -> 0.37 on SGLT2i, also not signif https://t.co/TviFyAwXbA
Aurelie Najm
2 years 11 months ago
Insights into pathogenesis venous & arterial thrombosis in RA + JAKi
Significant dysregulation of clotting pathways in myeloid & increased clot formation in context of microbial challenge (TLR4)
Observed across all JAKI, but selective JAK3i
@RheumNow #ACR23 ABST1676 https://t.co/nboy0znfAW
Richard Conway
2 years 11 months ago
Suarez-Almazor et al. TNFi in early breast cancer do not impact overall survival, HR=0.75 (0.41-1.37), HR=0.86 (0.55-1.34). Better cancer specific survival HR=0.29 ( 0.09-0.98)! Abstr#1675 #ACR23 #ACRbest @RheumNow https://t.co/qS5W7WehiN
Dr. Antoni Chan
2 years 11 months ago
Two-week interruption of MTX for IMIDs enhanced boost of antibody responses after COVID-19 vaccination, sustained at 12, 26 weeks. Consistent across ages, MTX doses, route, IMIDs, primary vaccination platform,COVID-19, Abhishek A Abst#1677 #ACR23 @RheumNow https://t.co/T0KdsGh6vg
Aurelie Najm
2 years 11 months ago
VROOM 🏎️ study
2 wks interruption of MTX just after COVID vaccine:
-Increase S1-RBD Ab response for 26 wks
-Improves Neutralizing Ab titres (Wuhan Hu-1)
-Leads to more flares wks 4 & 12
Greater effect when MTX dose>15mg
@RheumNow #ACR23 ABST1677 https://t.co/SJmaRHtbRH
Richard Conway
2 years 11 months ago
Abishek et al. 2 week break from MTX enhances response to COVID-19 vaccination, mirroring what we saw for flu. Trade off is short term worsening of disease activity. Abstr#1677 #ACR23 @RheumNow https://t.co/gguRWER81x https://t.co/1hncvDTahH
Dr. Antoni Chan
2 years 11 months ago
There was a lower hazard ratio for incident cancer with exposure to TNFi compared to non-TNFi (RTX and ABA) and JAKi. Limits: potential for residual confounding by indication and small number of outcomes per drug class, Xavier S, Abst#1678 #ACR23 @RheumNow https://t.co/vJpFwl6Ivj
Eric Dein
2 years 11 months ago
A#1403 #ACR23 @RheumNow
17% of 1st degree relatives of AS pts have MRI-defined sacroiliitis
Study of 100 subjects w FHx AS
- 13/100: new dx of AxSpA, 7 w radiographic changes
- 4/100: Sacroiliitis without back pain
- 1 periph SpA
- 12 met clinical ASAS classification but not dx https://t.co/V7LCbaDXBe
Methotrexate is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. In the SMART study, Prasad et al. present the first RCT comparing either single dose (25 mg) or split-dose (10 mg morning, 15 mg evening, same day) once weekly MTX for 24 weeks.
Dr. John Cush RheumNow
2 years 11 months ago
OA and Syncope #ACR23
OA patient on NSAIDs presents with a peptic ulcer and GI Bleed.
https://t.co/vhRnv6dPim https://t.co/H4gsCivyxN
Eric Dein
2 years 11 months ago
GCs Major Driver of Depression in SLE Ab#1446 #ACR23
@RheumNow
1463 pts with SLE, prospective longitudinal study GC use: 49-57% of pts Prevalence of depression at any time: 89.8%, most of time 35%!! Risk factors: - Fibromyalgia OR 2.9 - GC OR 1.85
